1993
DOI: 10.1007/bf01053935
|View full text |Cite
|
Sign up to set email alerts
|

Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) Lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
19
0
1

Year Published

1995
1995
2020
2020

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 38 publications
(20 citation statements)
references
References 38 publications
0
19
0
1
Order By: Relevance
“…Ibayashi et al [7] reported partial tumor response in 3 of 9 patients with malignant brain tumors. Jeffes et al [8] reported that 3 of 11 patients had a decrease in tumor size of 7 of 11 patients with recurrent high-grade glioma clinically improved after treatment with IL-2-stimulated killer cells. Merchant et al [9] treated 29 patients with brain tumors with intercavitary IL-2 LAK/treatment.…”
Section: Adoptive Immunotherapymentioning
confidence: 99%
“…Ibayashi et al [7] reported partial tumor response in 3 of 9 patients with malignant brain tumors. Jeffes et al [8] reported that 3 of 11 patients had a decrease in tumor size of 7 of 11 patients with recurrent high-grade glioma clinically improved after treatment with IL-2-stimulated killer cells. Merchant et al [9] treated 29 patients with brain tumors with intercavitary IL-2 LAK/treatment.…”
Section: Adoptive Immunotherapymentioning
confidence: 99%
“…7 In total, 12 clinical trials were conducted using either LAK cells, or targeted T-cell therapies. [8][9][10][11][12][13][14][15][16][17][18] Quattrocci treated patients with gliomas with intra-lesional TIL and IL-2 19 leading to clinically relevant responses, i.e., one patient experienced a complete response, two patients a partial response and three patients progressed. Given the promising results from patients with melanoma and from patients with epithelial cancer, TIL therapy may also represent a viable option for the biological therapy of patients with glioma.…”
Section: Introductionmentioning
confidence: 99%
“…Several experimental immunotherapy models (1) and clinical trials (2,3) have been attempted, emphasizing patients with tumor recurrence (4,5). Current therapy consists of surgical resection, radiation, and chemotherapy but are, in general, palliative and a new treatment modality is needed.…”
Section: Introductionmentioning
confidence: 99%